Waltz Health ↔ Self-insured employers (platform)
United States · 2025-11
Waltz Health launched a direct-to-employer access model for GLP-1 obesity management medications in November 2025. The platform allows self-insured employers to offer tirzepatide and semaglutide at transparent, contracted prices without traditional PBM markup.
Model: Transparent Pricing
Status: active
Lives: Not disclosed
Savings: Lower net cost on obesity management drugs vs. traditional PBM